-transparent.png){kind=logo}
Objective: To describe the clinical manifestations, neuroimaging, cerebrospinal fluid(CSF) cytology and prognosis of Leptomeningeal metastases(LM). Methods: The clinical manifestations, imaging features and CSF cytology of LM patients admitted to Henan Provincial People's Hospital from May 1, 2015 to May 31, 2020 were retrospectively analyzed. The overall survival (OS) was evaluated by the time from the diagnosis of LM to death. Results: A total of 88 patients with LM were enrolled in the study, and the median age was 59 years (range:28-78 years). There were 42 males (47.7%) and 46 females (52.3%). According to the pathological classification, it was lung cancer in 58 cases (65.9%), gastric cancer in 13 cases (14.8%), breast cancer in 7 cases (8.0%), melanoma in 1 case, esophageal cancer in 1 case, gallbladder cancer in 1 case, renal cell carcinoma in 1 case, double source cancer in 2 cases, and unknown source in 4 cases. The median Karnofsky Performance Scale (KPS) score was 50. LM was the initial manifestation of cancer in 34 patients. All patients had LM-related clinical symptoms, including headache in 73 cases (83.0%), nausea and vomiting in 63 cases (71.6%), abnormal physical and mental behaviors in 37 cases (42.0%), seizure in 41 cases (46.6%). Cranial nerve involvement was observed in 23 patients (39.0%) and spinal nerve involvement in 20(33.9%). There were 61 patients (83.6%) who showed neuroimaging features of LM. Tumor cells or atypical cells were found in 90.8% of patients for the first time, and activated monocytes in 47 cases (54.7%). The median OS was 13.0 weeks (95%CI:2.9-23.1) with the 1-year survival rate of 19.1%. Univariate analysis of survival indicated that lung cancer, lower KPS score, tyrosine kinase inhibitors (TKIs) and whole brain radiotherapy were favorable predictors of survival (P<0.05). Conclusions: The overall prognosis of LM is poor. Good physical condition, TKIs treatment and whole brain radiotherapy might improve clinical outcomes of LM patients.
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
November 2013,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
November 1999,
Clinical radiology,
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
January 2007,
World journal of gastroenterology,
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
October 2013,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
February 2022,
Cellular and molecular biology (Noisy-le-Grand, France),
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
April 2008,
Neuro-oncology,
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
January 2019,
ESMO open,
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
January 2019,
Cancer management and research,
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
December 1990,
Journal of neuro-oncology,
M L Zhang, and
W F Ma, and
X Y Gao, and
Y Y Shi, and
H Q Liu, and
Y S Jiang, and
L Z Qin, and
L P Yuan, and
W Li, and
J W Zhang
July 1999,
Neurology,
